1. Home
  2. NCMI vs DMAC Comparison

NCMI vs DMAC Comparison

Compare NCMI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$4.10

Market Cap

414.7M

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$9.40

Market Cap

457.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
DMAC
Founded
2005
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
414.7M
457.2M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
NCMI
DMAC
Price
$4.10
$9.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$6.88
$15.50
AVG Volume (30 Days)
422.5K
581.8K
Earning Date
10-30-2025
11-12-2025
Dividend Yield
2.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$236,300,000.00
N/A
Revenue This Year
$3.66
N/A
Revenue Next Year
$12.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.81
$3.19
52 Week High
$7.60
$10.42

Technical Indicators

Market Signals
Indicator
NCMI
DMAC
Relative Strength Index (RSI) 46.27 69.32
Support Level $4.06 $7.76
Resistance Level $4.25 $10.42
Average True Range (ATR) 0.13 0.71
MACD 0.00 0.09
Stochastic Oscillator 22.22 64.37

Price Performance

Historical Comparison
NCMI
DMAC

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: